OTLK

$0.44-0.59%visit website

Outlook Therapeutics, Inc.

Market Cap

$106M

Live price × SEC shares (Aug 14, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.70

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Sep 30, 2025	Q1 FY2026 Dec 31, 2025	Q2 FY2026 Mar 31, 2026	Q3 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	(91.8)
Cost of revenue	917	30	149	17	1,112
Gross profit	(1,008)	(1,237)	(22)	(8)	(2,276)
Research & development	5,979	3,634	4,501	3,251	17,365
Selling, general & administrative	10,328	8,612	9,505	7,551	35,995
Operating income	(17,315)	(13,484)	(14,027)	(10,810)	(55,636)
Pretax income	(14,847)		(4,453)	(20,319)
Income tax	(1,555)
Net income	(13,293)	(23,058)	(4,453)	(20,319)	(61,123)
EPS (basic) ($)		(0.38)	(0.05)	(0.15)	—
EPS (diluted) ($)		(0.38)	(0.05)	(0.15)	—
Weighted avg. shares (basic)		60,205	81,836	136,743
Weighted avg. shares (diluted)		60,205	81,836	136,743

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 18, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 42 more quarters, back to Mar 2015, with Tormere Pro.

Signals

purchases / sales, 90d

Short Volume

56%

W/W -15.9pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

2.12x

Avg Daily Buying (90d)

30,864 sh/day

Baseline Daily Buying

37,265 sh/day

Unique Buyers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-14	2026-08-14	KENYON LAWRENCE A	Director & Chief Financial Officer	Purchase	101.0K	—	—	107.0K	View
2026-08-14	2026-08-14	Jahr Robert Charles	Director & Chief Executive Officer	Purchase	151.5K	—	—	151.5K	View
2026-08-12	2026-08-14	Sukhtian Ghiath M.	Director	Purchase	2.53M	$0.99	$2.50M	24.62M	View
2026-07-29	2026-07-29	Sukhtian Faisal Ghiath	Director	Purchase	95.4K	$1.05	$100K	221.0K	View
2026-06-02	2026-06-03	Haddadin Yezan Munther	Director	Purchase	29.0K	$0.83	$24K	66.2K	View

1–5 of 10

1 / 2

Recent News

Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine

MarketWatch · 2026-11-06

DraftKings Cuts Outlook as It Pours More Money Into Prediction Markets

WSJ · 2026-11-05

This Is the Number That Could Change Nvidia Stock’s Outlook for 2027

24/7 Wall St. · 2026-11-05

Rheinmetall shares plunge 16% after outlook cut as military contracts stall

CNBC · 2026-11-05

Expedia’s Stock Gives Back Some Gains After Murky Outlook

Barron's · 2026-11-05

Outlook Therapeutics Inc (OTLK) Stock Price Target & Forecast

TradingKey · 2026-11-04

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Yahoo · 2026-10-09

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Yahoo Finance · 2026-09-11

Travere Therapeutics' Outlook Brightens As Turnaround Looms

Yahoo Finance · 2026-09-08

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Yahoo Finance · 2026-08-27

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Yahoo Finance · 2026-08-17

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Yahoo Finance · 2026-08-14

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Yahoo Finance · 2026-08-14

Why Did OTLK Stock Crash In Pre-Market Today?

Yahoo Finance · 2026-08-13

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Yahoo Finance · 2026-08-12

Informational purposes only, not investment advice.

OTLK

Financial Statements

Signals

Factor Profile

Recent News

Outlook Therapeutics, Inc. (OTLK)

Reporting Insiders

Factor Profile

Date	Insider	Type	Shares	Value
2026-08-14	KENYON LAWRENCE A	P	101,010	—
2026-08-14	Jahr Robert Charles	P	151,515	—
2026-08-12	Sukhtian Ghiath M.	P	2,525,252	$2M
2026-07-29	Sukhtian Faisal Ghiath	P	95,398	$99,996.18
2026-06-02	Haddadin Yezan Munther	P	29,000	$24,145.4